Prior Ibrutinib May Improve CAR-T Efficacy in Rare Lymphoma

(MedPage Today) — Prior exposure to ibrutinib (Imbruvica) in patients with mantle cell lymphoma (MCL) was associated with improved efficacy following treatment with chimeric antigen receptor (CAR) T-cell therapy brexucabtagene autoleucel…